← All trials
NCT06313190
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 5, 2024
- Primary completion
- Apr 30, 2028
- Completion date
- Apr 30, 2030
- First posted
- Mar 15, 2024
- Last posted
- Mar 15, 2024
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Sun Yat-Sen UniversityCollaborator
- Sun Yat-Sen UniversityOfficial
- Ningbo Medical Center Lihuili Eastern HospitalCollaborator
- Sun Yat-Sen UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.